Page last updated: 2024-11-06

glisentide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Glisentide is a novel synthetic peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R). It is being investigated as a potential treatment for type 2 diabetes. Glisentide has been shown to stimulate insulin secretion, suppress glucagon secretion, and slow gastric emptying. In clinical trials, glisentide has demonstrated significant improvements in glycemic control in patients with type 2 diabetes. The synthesis of glisentide involves the use of solid-phase peptide synthesis techniques. Glisentide is studied because it is a promising new treatment option for type 2 diabetes, offering several potential benefits over existing therapies. These benefits include improved efficacy, fewer side effects, and a more convenient dosing schedule. Glisentide is being investigated for its potential to treat type 2 diabetes. It is a synthetic peptide that acts as an agonist of the GLP-1 receptor. Glisentide has shown promising results in clinical trials, with significant improvements in glycemic control. The compound's effects include increased insulin secretion, reduced glucagon secretion, and slowed gastric emptying. Glisentide's importance lies in its potential to offer a new and effective treatment option for type 2 diabetes.'

glisentide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65779
CHEMBL ID2105089
CHEBI ID135725
SCHEMBL ID37753
SCHEMBL ID20657516
MeSH IDM0353033

Synonyms (36)

Synonym
glisentide
staticum (tn)
glypentide
glisentide (inn)
32797-92-5
D02428
CHEBI:135725
n-[2-[4-(cyclopentylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide
glipentidum
ur-661
staticum
glisentida [inn-spanish]
n-(4-(beta-o-anisamidoethyl)benzenesulfonyl)-n'-cyclopentylcarbamide
392tql1e2z ,
unii-392tql1e2z
glipentidum [inn-latin]
glipentida
glisentidum [latin]
glisentida [spanish]
glisentidum [inn-latin]
einecs 251-226-3
n-(2-(4-((((cyclopentylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide
glisentida
glisentidum
glipentide
glipentida [inn-spanish]
1-cyclopentyl-3-((p-(2-(o-anisamido)ethyl)phenyl)sulfonyl)urea
glisentide [inn]
CHEMBL2105089
glisentide [who-dd]
glisentide [mart.]
SCHEMBL37753
DTXSID10186465
SCHEMBL20657516
glisentide;staticum;ur661;
Q27256848
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (57.14)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]